Care365.caYour health is one click away
Menu
Book with Care365

Meningococcal

Meningococcal (Men-C, ACYW, Men-B)

MENVEO · NIMENRIX · MENQUADFI · NEISVAC-C · BEXSERO · TRUMENBA

Routine toddler and adolescent doses; extra doses for higher-risk conditions. Every product below is a Health Canada authorized vaccine; every schedule comes from the Canadian Immunization Guide.

How many doses do I need? →

Products
7
Dose schedules
10
Guidance checked
2026-09-27

Authorized products

Brand names and DINs (Drug Identification Numbers) as Health Canada's Drug Product Database lists them. The product monograph is the manufacturer's full prescribing information approved by Health Canada.

Before and after vaccination

  • Bring your immunization record so earlier doses can be checked.
  • Discuss a serious reaction to a previous vaccine, relevant health conditions, medicines and allergies before receiving a dose.
  • After vaccination, stay where you can be observed for at least 15 minutes and report feeling faint or signs of an allergic reaction right away.
  • Keep the vaccine name, date and dose in your immunization record.

Based on the Canadian Immunization Guide's administration practices and acute reactions guidance.

Pregnancy & breastfeeding

Pregnancy

Recommended when there is a high-risk condition, travel, an exposure or an outbreak.

Breastfeeding

Recommended when there is a high-risk condition, travel, an exposure or an outbreak.

Source: Immunization in pregnancy and breastfeeding: Canadian Immunization Guide — Chapter updated August 2026. Live vaccines are generally contraindicated in pregnancy; routinely recommended vaccines can be given while breastfeeding unless the chapter says otherwise.

How many doses

The schedules the Canadian Immunization Guide describes for this vaccine. Which one applies depends on age, health and product — use the dose planner to see the dates for your situation.

Meningococcal ACYW — toddler dose at 12 to 23 months

1 dose

One dose of quadrivalent (Men-C-ACYW) conjugate vaccine at 12 to 23 months.

NACI (May 2026): all children 12 to 23 months of age should receive one dose of quadrivalent meningococcal conjugate (Men-C-ACYW) vaccine, replacing the Men-C-C toddler dose. A child who already had Men-C-C at 12 to 23 months is not revaccinated. MENQUADFI is authorized from 12 months, NIMENRIX from 6 weeks, MENVEO from 2 months.

ProductsMENVEONIMENRIXMENQUADFI

Meningococcal ACYW — routine adolescent or adult, one dose

1 dose

One dose of Men-C-ACYW conjugate vaccine, routinely given at about 12 years of age.

Routine single adolescent dose regardless of infant or toddler history; also for adults with travel, occupational or outbreak indications.

ProductsMENVEONIMENRIXMENQUADFI

Meningococcal ACYW — high-risk conditions, two doses

2 doses

Two doses 8 weeks apart for asplenia, complement deficiency, HIV and other high-risk conditions.

For people 12 months and older with no spleen or a spleen that does not work, complement or properdin deficiency (including eculizumab or ravulizumab treatment), HIV, or other high-risk conditions. Two doses at least 8 weeks apart (4 weeks if accelerated). A booster every 5 years while risk continues (every 3 years if first immunized under 7 years of age).

ProductsMENVEONIMENRIXMENQUADFI

Meningococcal C (NEISVAC-C) — toddler dose at 12 to 23 months (older provincial programs)

1 dose

One dose of Men-C-C conjugate vaccine at 12 to 23 months, where a province still uses it.

The CIG chapter recommends one dose of Men-C-C at 12 to 23 months regardless of infant doses. NACI (May 2026) now recommends a quadrivalent (Men-C-ACYW) dose at this age instead; a child who already had Men-C-C at 12 to 23 months is not revaccinated.

ProductsNEISVAC-C

Meningococcal B (BEXSERO) — infants starting at 2 to 5 months

3 doses

Two doses 8 weeks apart plus a booster at 12 to 23 months of age.

For infants starting at 2 to 5 months of age when recommended (high-risk conditions, outbreak control or provincial programs): two (or three) primary doses at least 8 weeks apart, then a booster in the second year of life (12 to 23 months of age).

ProductsBEXSERO

Meningococcal B (BEXSERO) — infants starting at 6 to 11 months

3 doses

Two doses at least 8 weeks apart plus a booster at 12 to 23 months of age.

For infants starting at 6 to 11 months of age: two doses at least 8 weeks apart, then a booster in the second year of life (12 to 23 months of age).

ProductsBEXSERO

Meningococcal B (BEXSERO) — 12 months to 10 years, two doses

2 doses

Two doses at least 8 weeks apart.

For children 12 months to 10 years of age at increased risk (asplenia, complement deficiency, outbreak) or by individual decision: two doses at least 8 weeks apart.

ProductsBEXSERO

Meningococcal B (BEXSERO) — 11 years and older, two doses

2 doses

Two doses at least 4 weeks apart.

For people 11 years of age and older at increased risk (asplenia, complement deficiency, laboratory exposure, outbreak) or by individual decision: two doses at least 4 weeks apart.

ProductsBEXSERO

Meningococcal B (TRUMENBA) — 10 years and older, two doses

2 doses

Two doses 6 months apart for people 10 years and older who are not at high risk.

TRUMENBA is authorized for 10 years of age and older. Routine two-dose schedule at 0 and 6 months. High-risk people need the three-dose schedule instead.

ProductsTRUMENBA

Meningococcal B (TRUMENBA) — high-risk conditions, three doses

3 doses

Three doses at 0, 1 to 2 and 6 months for high-risk people 10 years and older.

For asplenia, complement deficiency, HIV and other high-risk conditions from 10 years of age. Dose 2 at least 4 weeks after dose 1; dose 3 at least 4 months after dose 2 and at least 6 months after dose 1.

ProductsTRUMENBA

Open the dose planner

References and product information

Clinical rules reviewed on 2026-09-27. General information from public Canadian guidance; a personal assessment is needed for treatment decisions. Care365 does not decide whether a vaccine is publicly funded in Ontario.